Skip to main content
Shanghai ZJ Bio-Tech Co., Ltd logo

Shanghai ZJ Bio-Tech Co., Ltd — Investor Relations & Filings

Ticker · 688317 ISIN · CNE100005DB6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-04-24 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688317

About Shanghai ZJ Bio-Tech Co., Ltd

https://m.liferiver.com.cn/

Shanghai ZJ Bio-Tech Co., Ltd., operating under the brand Liferiver, specializes in the development, manufacture, and distribution of molecular diagnostic reagents and equipment. The company’s core expertise lies in real-time PCR technology, providing a comprehensive portfolio of over 400 diagnostic kits. These solutions target a broad spectrum of infectious diseases, including viral hepatitis, respiratory infections, sexually transmitted diseases, and zoonotic pathogens. Beyond clinical diagnostics, the company offers specialized kits for food safety testing and veterinary health monitoring. Its products are utilized by clinical laboratories, hospitals, and public health institutions worldwide. Many diagnostic assays have achieved international recognition through CE marking and World Health Organization (WHO) listings. The company focuses on delivering high-sensitivity, high-specificity molecular tools to facilitate rapid pathogen detection and disease management.

Recent filings

Filing Released Lang Actions
之江生物：2024年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '2024年度审计报告' which translates to '2024 Annual Audit Report' for Shanghai Zhijiang Biotechnology Co., Ltd. It contains an auditor's opinion, detailed financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes to the financial statements. The content includes audit basis, key audit matters, management and auditor responsibilities, and detailed financial data for the fiscal year ending December 31, 2024. This matches the characteristics of a standalone Audit Report rather than a full Annual Report (10-K) or other filings. The length is substantial (15,000 characters), and it contains the full audit report and financial statements, not just an announcement or certification. Therefore, the correct classification is Audit Report / Information (AR).
2025-04-24 Chinese
之江生物：2024年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Shanghai Zhijiang Bio-Technology Co., Ltd. regarding the 2024 profit distribution plan. It details the company's decision not to distribute cash dividends, not to issue bonus shares, and not to convert capital reserves into shares. It includes audited net profit figures, references to regulatory rules, and mentions that the plan requires shareholder approval at the upcoming general meeting. The document is relatively short (2841 characters) and primarily serves as a formal announcement of the profit distribution plan rather than a full financial report or detailed analysis. It does not contain comprehensive financial statements or detailed management discussion. Therefore, it fits best as a Notice of Dividend Amount (DIV) announcement, as it communicates dividend distribution decisions and related financial data to shareholders.
2025-04-24 Chinese
之江生物：董事会审计委员会2024年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board Audit Committee 2024 Annual Performance Report" of Shanghai Zhijiang Biotechnology Co., Ltd. It details the audit committee's activities, meetings, supervision of external audit work, review of financial statements, internal audit guidance, and internal control evaluation for the year 2024. The content focuses on the audit committee's duties and oversight rather than presenting full financial statements or a standalone audit opinion. The document length is 2616 characters, which is relatively short and more of a committee report rather than a full audit report. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial data. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content about the audit committee's work. The document fits best as an Audit Report / Information (AR) since it is a standalone report on audit committee activities and audit oversight for the year, without being the full annual report itself.
2025-04-24 Chinese
之江生物：第五届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th meeting of the 5th Supervisory Board of Shanghai Zhijiang Bio-technology Co., Ltd. It details the meeting attendance, voting results, and approvals of various proposals including the 2024 financial statements, annual report, audit firm reappointment, use of raised funds, asset impairment provisions, profit distribution, supervisory board work report, and remuneration proposals. The document is a meeting resolution announcement rather than the actual financial report or audit report itself. It does not contain detailed financial statements or substantive financial data but rather the supervisory board's approval and recommendations to submit these reports to the shareholders' meeting. The document length is 2417 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS) as a formal regulatory announcement of supervisory board meeting resolutions and approvals related to financial and governance matters.
2025-04-24 Chinese
之江生物：2024年年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and usage of funds raised by Shanghai Zhijiang Bio-technology Co., Ltd. during the year 2024. It includes specifics on the amount raised, the timing of fund receipt, usage of funds, cash management of idle funds, and compliance with regulatory requirements. The report references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes auditor and sponsor institution opinions on the fund usage. The document is titled as a "专项报告" (special report) on the annual fundraising funds storage and usage situation, which is a typical format for a fundraising usage report rather than a general annual report or earnings release. It is not an announcement of a report publication but the report itself, given its length (over 10,000 characters) and detailed content. The content focuses on capital raised and its management, fitting the category of Capital/Financing Update (CAP).
2025-04-24 Chinese
之江生物：2024年度营业收入扣除情况的专项审核说明
Audit Report / Information Classification · 95% confidence The document is a specialized audit report on the deduction of operating income for Shanghai Zhijiang Biotechnology Co., Ltd. for the year 2024. It includes an auditor's opinion, references to the 2024 financial statements, and detailed tables of income deductions. The document is issued by a registered CPA firm and contains substantive financial data and audit conclusions specific to the operating income deductions, which is a form of audit report but not a full annual report. It is not a simple announcement or certification but a detailed audit opinion on a specific financial aspect. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (6640 characters) supports it being a full report rather than a brief announcement.
2025-04-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.